{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:50Z","timestamp":1791312830243,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"27-28","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.vaccine.2008.04.017","type":"journal-article","created":{"date-parts":[[2008,4,29]],"date-time":"2008-04-29T16:13:48Z","timestamp":1209485628000},"page":"3507-3515","source":"Crossref","is-referenced-by-count":48,"title":["Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies"],"prefix":"10.1016","volume":"26","author":[{"given":"Joseph W.","family":"Golden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Josleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5788","key":"10.1016\/j.vaccine.2008.04.017_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.1125134","article-title":"Genome sequence diversity and clues to the evolution of variola (smallpox) virus","volume":"313","author":"Esposito","year":"2006","journal-title":"Science"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2008.04.017_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1099\/0022-1317-83-4-855","article-title":"The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox","volume":"83","author":"Gubser","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib3","doi-asserted-by":"crossref","unstructured":"Werden SJ, McFadden G. The role of cell signaling in orthopoxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim Biophys Acta; Aug 14, 2007 [epub ahead of print].","DOI":"10.1016\/j.bbapap.2007.08.001"},{"key":"10.1016\/j.vaccine.2008.04.017_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00001432-200404000-00003","article-title":"Zoonotic orthopoxvirus infections in humans","volume":"17","author":"Lewis-Jones","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2008.04.017_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/17460913.2.1.17","article-title":"Human monkeypox: an emerging zoonotic disease","volume":"2","author":"Parker","year":"2007","journal-title":"Future Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2008.04.017_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa032299","article-title":"The detection of monkeypox in humans in the Western Hemisphere","volume":"350","author":"Reed","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2008.04.017_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1045-1870(03)00032-3","article-title":"Adverse events occurring after smallpox vaccination","volume":"14","author":"Lane","year":"2003","journal-title":"Semin Pediatr Infect Dis"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2008.04.017_bib8","first-page":"1","article-title":"Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC)","volume":"52","author":"Wharton","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2008.04.017_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(03)00008-1","article-title":"Pathogenesis and potential antiviral therapy of complications of smallpox vaccination","volume":"58","author":"Bray","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2008.04.017_bib10","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1371\/journal.pmed.0030272","article-title":"Frequency of adverse events after vaccination with different vaccinia strains","volume":"3","author":"Kretzschmar","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2008.04.017_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2008.04.017_bib12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2008.04.017_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib14","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2008.04.017_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1086\/427265","article-title":"Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge","volume":"191","author":"Edghill-Smith","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2008.04.017_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","article-title":"Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host","volume":"345","author":"Fang","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib18","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent orthopoxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal orthopoxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib22","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib23","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.vaccine.2006.11.017","article-title":"Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal orthopoxvirus challenge","volume":"25","author":"Hooper","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.04.017_bib24","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib25","series-title":"Fields virology","first-page":"1249","article-title":"Orthopoxviruses and their replication","author":"Moss","year":"2001"},{"key":"10.1016\/j.vaccine.2008.04.017_bib26","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1128\/JVI.64.12.5988-5996.1990","article-title":"Use of a cell-free system to identify the vaccinia virus L1R gene product as the major late myristylated virion protein M25","volume":"64","author":"Franke","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib27","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1128\/JVI.68.10.6401-6410.1994","article-title":"Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly","volume":"68","author":"Ravanello","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/viro.1996.0337","article-title":"Neutralizing epitope on penetration protein of vaccinia virus","volume":"220","author":"Ichihashi","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/viro.1994.1405","article-title":"Identification of a vaccinia virus penetration protein","volume":"202","author":"Ichihashi","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/viro.1995.1378","article-title":"A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies","volume":"211","author":"Wolffe","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib31","unstructured":"Hooper JW, Schmaljohn AL, Schmaljohn C, Inventors; The United States of America as represented by the Secretary of the Army, Assignee. Prophylactic and Therapeutic Monoclonal Antibodies. United States of America Patent 6,451,309; 2002."},{"key":"10.1016\/j.vaccine.2008.04.017_bib32","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0501103102","article-title":"The 1.51-Angstrom structure of the orthopoxvirus L1 protein, a target of potent neutralizing antibodies","volume":"102","author":"Su","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2008.04.017_bib33","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1073\/pnas.062163799","article-title":"Complete pathway for protein disulfide bond formation encoded by orthopoxviruses","volume":"99","author":"Senkevich","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2008.04.017_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.virol.2007.06.042","article-title":"Structural basis for the binding of the neutralizing antibody, 7D11, to the orthopoxvirus L1 protein","volume":"368","author":"Su","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.vaccine.2008.04.017_bib36","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/JVI.00115-06","article-title":"Protective immunity against secondary orthopoxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function","volume":"80","author":"Panchanathan","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib37","doi-asserted-by":"crossref","unstructured":"Panchanathan V, Chaudhri G, Karupiah G. Correlates of protective immunity in orthopoxvirus infection: where does antibody stand? Immunol Cell Biol; Oct 9, 2007 [epub ahead of print].","DOI":"10.1038\/sj.icb.7100118"},{"key":"10.1016\/j.vaccine.2008.04.017_bib38","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1128\/JVI.71.12.9563-9569.1997","article-title":"Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge","volume":"71","author":"Schmaljohn","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/JVI.61.2.395-404.1987","article-title":"A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers","volume":"61","author":"Rodriguez","year":"1987","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib40","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.158.5.2278","article-title":"Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization","volume":"158","author":"Feltquate","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2008.04.017_bib41","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal orthopoxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.04.017_bib42","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.virol.2005.07.006","article-title":"Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene","volume":"341","author":"Aldaz-Carroll","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2008.04.017_bib43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0264-410X(01)00492-3","article-title":"Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model","volume":"20","author":"Ashok","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.04.017_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.virusres.2005.05.002","article-title":"DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response","volume":"113","author":"Rath","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2008.04.017_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.vaccine.2005.07.059","article-title":"Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence","volume":"24","author":"Costa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.04.017_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.70.1.292-302.2002","article-title":"DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis","volume":"70","author":"Delogu","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.04.017_bib47","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/IAI.67.9.4780-4786.1999","article-title":"Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences","volume":"67","author":"Li","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2008.04.017_bib48","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1016\/j.vaccine.2004.02.036","article-title":"A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague","volume":"22","author":"Wang","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.04.017_bib49","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","article-title":"Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges","volume":"25","author":"Fogg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2008.04.017_bib50","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08004556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08004556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:14:50Z","timestamp":1684368890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08004556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":50,"journal-issue":{"issue":"27-28","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0264410X08004556"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.04.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}